Evidence map›Paper›PMID 29374467›Full record

ArticleBMC infectious diseases2018

The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016.

Bassey Enya Bassey, Fiona Braka, Rui Gama Vaz, William Komakech, Sylvester Toritseju Maleghemi, Richard Koko, Thompson Igbu, Faith Ireye, Sylvester Agwai, Godwin Ubong Akpan and 3 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bassey Enya BasseyWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria. bassey69@yahoo.com.
Fiona BrakaWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Rui Gama VazWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
William KomakechWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Sylvester Toritseju MaleghemiWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Richard KokoWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Thompson IgbuWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Faith IreyeWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Sylvester AgwaiWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Godwin Ubong AkpanWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Sisay Gashu TegegneWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Abdul-Aziz Garba MohammedWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.
Angela Okocha-EjekoWorld Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThe globally synchronized switch from trivalent Oral Polio Vaccine (tOPV) to bivalent Oral Polio Vaccine (bOPV) took place in Nigeria on April 18th 2016. The country is divided into six geopolitical zones. This study reports the experiences and lessons learned from the switch process in the six states that make up Nigeria's south-south geopolitical zone.

methodsThis was a descriptive retrospective review of Nigeria's switch plan and structures used for implementing the tOPV-bOPV switch in the south-south zone. Nigeria's National Polio Emergency Operation Centre (NPEOC) protocols, global guidelines and reports from switch supervisors during the switch were used to provide background information for this study. Quantitative data were derived from reviewing switch monitoring and validation documents as submitted to the NPEOC

resultsThe switch process took place in all 3078 Health Facilities (HFs) and 123 Local Government Areas (LGAs) that make up the six states in the zone. A total of $139,430 was used for this process. The 'healthcare personnel' component received the highest budgetary allocation (59%) followed by the 'logistics' component (18%). Akwa Ibom state was allocated the highest number of healthcare personnel and hence received the most budgetary allocation compared to the six states (total healthcare personnel = 458, total budgetary allocation = $17,428). Validation of the switch process revealed that eight HFs in Bayelsa, Cross-River, Edo and Rivers states still possessed tOPV in cold-chain while six HFs in Cross-River and Rivers states had tOPV out of cold-chain but without the 'do not use' sticker. Akwa-Ibom was the only state in the zone to have bOPV and Inactivated Polio Vaccine (IPV) available in all its HFs monitored.

conclusionThe Nigerian tOPV-bOPV switch was successful. For future Oral Polio Vaccine (OPV) withdrawals, implementation of the switch plan would be more feasible with an earlier dissemination of funds from global donor organizations, which would greatly aid timely planning and preparations. Increased budgetary allocation to the 'logistics' component to accommodate unexpected hikes in transportation prices and the general inefficiencies with power supply in the country is also advised.

Indexed as

HumansNigeriaPoliomyelitisPoliovirus Vaccine, OralRetrospective StudiesVaccinationPoliovirus Vaccine, OralbOPVSwitchtOPV

Identifiers

PMID29374467
PMCPMC5787308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.